Recursion is a very useful programming skill. You may not use it very often in most languages, but the ability to think recursively is a valuable skill to acquire. There are programming languages (e.g ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

As part of Microsoft’s Ignite conference, Stack Overflow on Tuesday revealed a new set of products that aims to position it as a valuable part of the enterprise AI stack. This new version of the ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

"The Board’s unanimous decision to appoint Najat Khan as Recursion’s next CEO is a clear reflection of our confidence in her strategic acumen and proven track record," said Hershberg. Khan joined ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...